The RASopathies: Syndromes of Ras/MAPK pathway dysregulation

William E. Tidyman, Katherine A Rauen

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

A class of clinically related developmental disorders, the RASopathies, has recently been shown to be caused by germline mutations in genes that encode components, or regulators, of the Ras/mitogen-activated protein kinase (MAPK) pathway. Neurofibromatosis type 1, the first syndrome identified to be caused by a germline mutation in this pathway, was followed by other syndromes including Noonan, Noonan with multiple lentigines, capillary malformation-AV malformation, Costello, cardio-facio-cutaneous, and Legius. The Ras/MAPK pathway plays an essential role in the regulation of the cell cycle, differentiation, growth, and cell senescence, all of which are critical to normal development. As a result, Ras/MAPK pathway dysregulation has been shown to have profound deleterious effects on both embryonic and later stages of development. Because the underlying molecular mechanism for these syndromes is dysregulation of the Ras/MAPK pathway, the RASopathies exhibit numerous overlapping phenotypic features, including reduced growth, characteristic facial features, cardiac defects, cutaneous abnormalities, neurocognitive delay, and a predisposition to neoplasia, both benign and malignant. As a group, the RASopathies are one of the largest recognizable patterns of malformation syndromes known, affecting approximately 1:1,000 individuals.

Original languageEnglish (US)
Title of host publicationNeurofibromatosis Type 1: Molecular and Cellular Biology
PublisherSpringer-Verlag Berlin Heidelberg
Pages497-511
Number of pages15
Volume9783642328640
ISBN (Electronic)9783642328640
ISBN (Print)3642328636, 9783642328633
DOIs
StatePublished - Aug 1 2012

Fingerprint

Mitogen-Activated Protein Kinases
Germ-Line Mutation
Skin Abnormalities
Lentigo
Noonan Syndrome
Gene Components
Neurofibromatosis 1
Cell Aging
Growth
Cell Differentiation
Cell Cycle
Genes
Cells
Skin
Defects
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Tidyman, W. E., & Rauen, K. A. (2012). The RASopathies: Syndromes of Ras/MAPK pathway dysregulation. In Neurofibromatosis Type 1: Molecular and Cellular Biology (Vol. 9783642328640, pp. 497-511). Springer-Verlag Berlin Heidelberg. https://doi.org/10.1007/978-3-642-32864-0_32

The RASopathies : Syndromes of Ras/MAPK pathway dysregulation. / Tidyman, William E.; Rauen, Katherine A.

Neurofibromatosis Type 1: Molecular and Cellular Biology. Vol. 9783642328640 Springer-Verlag Berlin Heidelberg, 2012. p. 497-511.

Research output: Chapter in Book/Report/Conference proceedingChapter

Tidyman, WE & Rauen, KA 2012, The RASopathies: Syndromes of Ras/MAPK pathway dysregulation. in Neurofibromatosis Type 1: Molecular and Cellular Biology. vol. 9783642328640, Springer-Verlag Berlin Heidelberg, pp. 497-511. https://doi.org/10.1007/978-3-642-32864-0_32
Tidyman WE, Rauen KA. The RASopathies: Syndromes of Ras/MAPK pathway dysregulation. In Neurofibromatosis Type 1: Molecular and Cellular Biology. Vol. 9783642328640. Springer-Verlag Berlin Heidelberg. 2012. p. 497-511 https://doi.org/10.1007/978-3-642-32864-0_32
Tidyman, William E. ; Rauen, Katherine A. / The RASopathies : Syndromes of Ras/MAPK pathway dysregulation. Neurofibromatosis Type 1: Molecular and Cellular Biology. Vol. 9783642328640 Springer-Verlag Berlin Heidelberg, 2012. pp. 497-511
@inbook{471b40f439ce439aafaa201ab749bd9e,
title = "The RASopathies: Syndromes of Ras/MAPK pathway dysregulation",
abstract = "A class of clinically related developmental disorders, the RASopathies, has recently been shown to be caused by germline mutations in genes that encode components, or regulators, of the Ras/mitogen-activated protein kinase (MAPK) pathway. Neurofibromatosis type 1, the first syndrome identified to be caused by a germline mutation in this pathway, was followed by other syndromes including Noonan, Noonan with multiple lentigines, capillary malformation-AV malformation, Costello, cardio-facio-cutaneous, and Legius. The Ras/MAPK pathway plays an essential role in the regulation of the cell cycle, differentiation, growth, and cell senescence, all of which are critical to normal development. As a result, Ras/MAPK pathway dysregulation has been shown to have profound deleterious effects on both embryonic and later stages of development. Because the underlying molecular mechanism for these syndromes is dysregulation of the Ras/MAPK pathway, the RASopathies exhibit numerous overlapping phenotypic features, including reduced growth, characteristic facial features, cardiac defects, cutaneous abnormalities, neurocognitive delay, and a predisposition to neoplasia, both benign and malignant. As a group, the RASopathies are one of the largest recognizable patterns of malformation syndromes known, affecting approximately 1:1,000 individuals.",
author = "Tidyman, {William E.} and Rauen, {Katherine A}",
year = "2012",
month = "8",
day = "1",
doi = "10.1007/978-3-642-32864-0_32",
language = "English (US)",
isbn = "3642328636",
volume = "9783642328640",
pages = "497--511",
booktitle = "Neurofibromatosis Type 1: Molecular and Cellular Biology",
publisher = "Springer-Verlag Berlin Heidelberg",

}

TY - CHAP

T1 - The RASopathies

T2 - Syndromes of Ras/MAPK pathway dysregulation

AU - Tidyman, William E.

AU - Rauen, Katherine A

PY - 2012/8/1

Y1 - 2012/8/1

N2 - A class of clinically related developmental disorders, the RASopathies, has recently been shown to be caused by germline mutations in genes that encode components, or regulators, of the Ras/mitogen-activated protein kinase (MAPK) pathway. Neurofibromatosis type 1, the first syndrome identified to be caused by a germline mutation in this pathway, was followed by other syndromes including Noonan, Noonan with multiple lentigines, capillary malformation-AV malformation, Costello, cardio-facio-cutaneous, and Legius. The Ras/MAPK pathway plays an essential role in the regulation of the cell cycle, differentiation, growth, and cell senescence, all of which are critical to normal development. As a result, Ras/MAPK pathway dysregulation has been shown to have profound deleterious effects on both embryonic and later stages of development. Because the underlying molecular mechanism for these syndromes is dysregulation of the Ras/MAPK pathway, the RASopathies exhibit numerous overlapping phenotypic features, including reduced growth, characteristic facial features, cardiac defects, cutaneous abnormalities, neurocognitive delay, and a predisposition to neoplasia, both benign and malignant. As a group, the RASopathies are one of the largest recognizable patterns of malformation syndromes known, affecting approximately 1:1,000 individuals.

AB - A class of clinically related developmental disorders, the RASopathies, has recently been shown to be caused by germline mutations in genes that encode components, or regulators, of the Ras/mitogen-activated protein kinase (MAPK) pathway. Neurofibromatosis type 1, the first syndrome identified to be caused by a germline mutation in this pathway, was followed by other syndromes including Noonan, Noonan with multiple lentigines, capillary malformation-AV malformation, Costello, cardio-facio-cutaneous, and Legius. The Ras/MAPK pathway plays an essential role in the regulation of the cell cycle, differentiation, growth, and cell senescence, all of which are critical to normal development. As a result, Ras/MAPK pathway dysregulation has been shown to have profound deleterious effects on both embryonic and later stages of development. Because the underlying molecular mechanism for these syndromes is dysregulation of the Ras/MAPK pathway, the RASopathies exhibit numerous overlapping phenotypic features, including reduced growth, characteristic facial features, cardiac defects, cutaneous abnormalities, neurocognitive delay, and a predisposition to neoplasia, both benign and malignant. As a group, the RASopathies are one of the largest recognizable patterns of malformation syndromes known, affecting approximately 1:1,000 individuals.

UR - http://www.scopus.com/inward/record.url?scp=84949177798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949177798&partnerID=8YFLogxK

U2 - 10.1007/978-3-642-32864-0_32

DO - 10.1007/978-3-642-32864-0_32

M3 - Chapter

AN - SCOPUS:84949177798

SN - 3642328636

SN - 9783642328633

VL - 9783642328640

SP - 497

EP - 511

BT - Neurofibromatosis Type 1: Molecular and Cellular Biology

PB - Springer-Verlag Berlin Heidelberg

ER -